Key result
Heparin reduced fibrin and platelet development in arteries and veins, while clopidogrel reduced both in arteries and reduced platelet accumulation in venous thrombosis.
Why the study?
Does heparin or clopidogrel reduce fibrin and platelet accumulation in murine models of arterial and venous thrombosis?
Does heparin or clopidogrel reduce fibrin and platelet accumulation in murine models of arterial and venous thrombosis?
Inhibition of one thrombotic component (platelets or coagulation) shows cross-modulatory effects on the other in both arterial and venous thrombosis models.
Answers are grounded in this paper and cite their sources.
May inform preclinical thrombosis research; leaves open clinical translation of cross-modulatory antithrombotic effects.
Pharmacologic inhibition of platelet activation and aggregation is a mainstay for reducing the incidence of arterial thrombosis, whereas anticoagulation is the primary approach for preventing the development of venous thrombosis. The effect of standard pharmacologic agents on their reciprocal vessel - anticoagulants on arterial thrombosis and platelet inhibitor on venous thrombosis - is relatively understudied. This study was designed to evaluate murine large-vessel arterial or venous thrombosis under conditions of either fibrin or platelet inhibition. In this study, heparin and clopidogrel were used as standard anticoagulant and platelet inhibitor, respectively, evaluating both large artery and vein thrombosis in mice, using in-vivo fluorescence imaging to simultaneously measure fibrin and platelet levels at the thrombus induction site. Heparin reduced both fibrin and platelet development in both arteries and veins, with stronger influences on fibrin accrual. Clopidogrel had a stronger effect in arteries, reducing both platelet and fibrin accumulation. Clopidogrel also reduced platelet accumulation with venous thrombosis, but the reductions in fibrin formation did not reach statistical significance. These findings illustrate the interactive role of platelet activity and coagulation in the development of large-vessel thrombosis, with inhibition of one thrombotic component showing profound effects on the other component in both arterial and venous thrombosis.
No takes yet. Share an insight, caveat, or question.
Cooley et al. (2013) studied Large-vessel arterial or venous thrombosis. Heparin and clopidogrel was evaluated on Fibrin and platelet levels at the thrombus induction site. Heparin reduced fibrin and platelet development in arteries and veins, while clopidogrel reduced both in arteries and reduced platelet accumulation in venous thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: